GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Retained Earnings

Gilead Sciences (BUE:GILD) Retained Earnings : ARS5,885,744 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Gilead Sciences's retained earnings for the quarter that ended in Dec. 2023 was ARS5,885,744 Mil.

Gilead Sciences's quarterly retained earnings increased from Jun. 2023 (ARS3,633,120 Mil) to Sep. 2023 (ARS5,599,900 Mil) and increased from Sep. 2023 (ARS5,599,900 Mil) to Dec. 2023 (ARS5,885,744 Mil).

Gilead Sciences's annual retained earnings increased from Dec. 2021 (ARS1,648,561 Mil) to Dec. 2022 (ARS2,629,925 Mil) and increased from Dec. 2022 (ARS2,629,925 Mil) to Dec. 2023 (ARS5,885,744 Mil).


Gilead Sciences Retained Earnings Historical Data

The historical data trend for Gilead Sciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Retained Earnings Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,158,890.55 1,170,325.74 1,648,560.73 2,629,925.48 5,885,744.01

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,629,925.48 3,007,303.72 3,633,119.97 5,599,900.05 5,885,744.01

Gilead Sciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Gilead Sciences  (BUE:GILD) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Gilead Sciences (BUE:GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.